Valuation: SourcingLink.net, Inc.

Market Cap 19.72L 16.89L 15.8L 14.47L 27.15L 19Cr 27.51L 1.87Cr 72.82L 9.48Cr 74.04L 72.43L 31Cr P/E 2003 *
-
P/E 2004 -
Enterprise Value 19.72L 16.89L 15.8L 14.47L 27.15L 19Cr 27.51L 1.87Cr 72.82L 9.48Cr 74.04L 72.43L 31Cr EV / Sales 2003
-
EV / Sales 2004 -
Free-Float
100%
Yield 2003 *
-
Yield 2004 -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+9.50% - - 19.72L
+0.88%+6.38%+76.86%+128.23% 1,11900Cr
+1.07%+3.80%+51.03%+61.48% 65TCr
+1.20%+6.21%+26.47%+76.45% 47TCr
+1.02%+5.77%+43.09%+47.70% 37TCr
+0.85%+4.07%+23.88%+41.58% 30TCr
+1.26%+6.81%+1.59%+14.67% 26TCr
+1.88%+5.81%+48.54%+68.52% 24TCr
+1.59%+2.09%-15.52%-52.29% 21TCr
+1.87%+5.61%+25.81%+92.42% 18TCr
Average +1.16%+4.97%+31.31%+53.20% 42.22TCr
Weighted average by Cap. +1.14%+5.09%+44.31%+72.55%

Financials

2003 2004
Net sales 32.8L 28.1L 26.29L 24.06L 45.16L 31Cr 45.76L 3.11Cr 1.21Cr 16Cr 1.23Cr 1.2Cr 52Cr 11.81L 10.12L 9L 9L 16.26L 11Cr 16.48L 1.12Cr 43.61L 5.68Cr 44.35L 43.38L 19Cr
Net income -15.2L -13.02L -12.18L -11.15L -20.93L -15Cr -21.21L -1.44Cr -56.13L -7.31Cr -57.07L -55.83L -24Cr -15.65L -13.41L -12.54L -11.48L -21.55L -15Cr -21.83L -1.48Cr -57.79L -7.52Cr -58.76L -57.49L -25Cr
Net Debt -13.46L -11.53L -10.79L -10L -18.53L -13Cr -18.78L -1.27Cr -49.71L -6.47Cr -50.54L -49.44L -21Cr 17T 14.56T 13.63T 12.47T 23.41T 16.27L 23.72T 2L 62.78T 8L 63.83T 62.44T 27.03L
Logo SourcingLink.net, Inc.
Oncology Pharma, Inc. is an oncology company. The Company is focused on licensing, developing, manufacturing and commercializing therapeutics. The Company’s research, development, and commercialization of therapeutic drugs and medical devices designed for the treatment of many types of cancers. The Company offers a portfolio, such as Nanosmart Pharmaceuticals Inc. (Nanosmart Pharmaceuticals). The Company’s NanoSmart platform technology is a human-derived, antinuclear antibody (ANA) that targets areas of necrosis present in solid tumors. Its anti-cancer drugs in combination with medications, for treating a variety of cancers, such as breast, ovarian, lung, bladder, Kaposi's sarcoma, lymphoma and acute lymphocytic leukemia is doxorubicin. Its portfolio also includes Connect2Med, Sybleu, Inc. and Regen.
Employees
-